title: [Anti-N-methyl-D aspartate receptor encephalitis - guideline to the challenges of diagnosis and therapy].
abstract: OBJECTIVE
  Anti-N-methyl-D-Aspartate encephalitis is a recently diagnosed autoimmune disorder with increasing significance. During this disease antibodies are produced against the subunit of the NMDA receptor, which cause different symptoms, both psychiatric and neurological. The aim of this publication is to introduce this disease, to facilitate the diagnosis and to recommend therapeutical guideline.
  
  
  METHODS
  In this review we summarized the relevant literature published between 2007 and 2015 giving emphasis on etiopathogenesis, diagnosis, differential diagnosis, treatment and prognosis.
  
  
  RESULTS
  In the etiology an underlying tumor or a viral agent should be considered. During the disease we can discern 3 periods: first prodromal viral infections-like symptoms can be seen, 1-2 weeks later psychiatric symptoms, such as aggression, sleep and behavior disturbances appear. After that neurological symptoms (tonic-clonic convulsions, aphasia, catatonia, orofacial dyskinesia, autonom lability, altered mental state) are typical, and the patient's condition deteriorates. For the correct diagnosis it is necessary to detect antibodies against the NMDA receptor from the serum and the liquor. Steroids, immunoglobulins and plasmaheresis are the first-line therapies. If the disease is unresponsive, then as a second-line therapy anti-CD 20 (Rituximab) and cyclophosphamid can be useful. Most of the patients are improving without any neurological sequale with prompt detection and appropriate therapy.
  
  
  CONCLUSIONS
  It is important to be familiar with the symptoms, diagnosis and therapy of this disease as a practicing clinician, especially as a psychiatrist or neurologist. 75 percentage of the patients are admitted to psychiatric departments first because of the leading symptoms. Autoimmune NMDA encephalitis is a reversible disease after early diagnosis and treatment.
authors.affiliation: Pecsi Tudomanyegyetem Klinikai Idegtudomanyok Doktori Iskola, Pszichiatria Program, Pecs, Hungary, E-mail: tenyi.tamas@pte.hu.
authors.forename: Lídia
authors.initials: L
authors.lastname: Hau
authors.forename: Györgyi
authors.initials: G
authors.lastname: Csábi
authors.forename: Tamás
authors.initials: T
authors.lastname: Tényi
mesh_terms: D000374:Aggression; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D060426:Anti-N-Methyl-D-Aspartate Receptor Encephalitis / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology / Q000523:psychology / Q000628:therapy* / Q000821:virology; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid*; D015551:Autoimmunity; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D009422:Nervous System Diseases / Q000209:etiology; D018696:Neuroprotective Agents / Q000008:administration & dosage; D010956:Plasmapheresis; D000066553:Problem Behavior; D011379:Prognosis; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology*; D000069283:Rituximab / Q000008:administration & dosage; D017678:Sex Distribution; D012893:Sleep Wake Disorders / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D000069283:Rituximab; D003520:Cyclophosphamide; D008775:Methylprednisolone